Strong Price Performance and Market Outperformance
On 16 Jun 2026, Sudeep Pharma Ltd’s stock recorded an intraday high of Rs.856.10, marking a new 52-week and all-time peak. The stock outperformed its sector by 3.66% on the day, closing with a gain of 1.58%, compared to the Sensex’s modest 0.46% rise. This marks the third consecutive day of gains, during which the stock has delivered a remarkable 17.08% return.
The stock’s upward trajectory is further supported by its position above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a sustained bullish trend. Over various time frames, Sudeep Pharma has consistently outpaced the broader market. Its one-week return stands at 12.55% versus the Sensex’s 3.65%, while the one-month gain is an impressive 28.93%, dwarfing the Sensex’s 1.83% rise.
Extending the horizon, the three-month performance shows a 40.19% increase against the Sensex’s 1.47%, and year-to-date returns are up 38.77%, contrasting with the Sensex’s decline of 10.10%. These figures underscore the stock’s resilience and strong relative strength within the Pharmaceuticals & Biotechnology sector.
Valuation Metrics Reflect Premium Pricing
As of 16 Jun 2026, at a price of Rs.836.00, Sudeep Pharma’s valuation multiples indicate a premium market positioning. The trailing twelve months (TTM) price-to-earnings (P/E) ratio stands at 54x, while the price-to-book value (P/BV) is 10.50x. Enterprise value multiples are also elevated, with EV/EBITDA at 41.95x and EV/EBIT at 44.95x, reflecting investor willingness to pay a premium for the company’s earnings and operational cash flow.
The EV/Sales multiple is 14.49x, and EV/Capital Employed is 10.13x, further highlighting the valuation premium. Dividend metrics are not applicable, as the company has not declared dividends recently, with a dividend payout ratio of zero.
Technical Analysis Indicates Mildly Bullish Momentum
The overall technical trend for Sudeep Pharma is classified as mildly bullish, a shift from a previous sideways trend that changed on 29 May 2026 at a price level of Rs.741.7. Key technical indicators provide a mixed but generally positive outlook. Bollinger Bands and Dow Theory signals are bullish on a weekly and monthly basis, respectively, while the On-Balance Volume (OBV) shows a mildly bullish trend monthly.
Immediate support is identified at Rs.524.95, the 52-week low, while resistance levels include Rs.721.62 (20-day moving average) and Rs.646.01 (100-day moving average). The stock’s recent ability to surpass these resistance points has contributed to its new high.
Delivery volumes have surged notably, with a 1-month delivery change of 91.6% and a 1-day delivery change of 60.86% compared to the 5-day average, indicating increased investor participation in recent sessions.
Quality Assessment Highlights Financial Strength
Sudeep Pharma’s quality assessment reveals a company with a strong financial foundation. Management risk is rated excellent, and the capital structure is robust, characterised by low leverage and no promoter share pledging. The company maintains a strong interest coverage ratio of 33.98x and an average debt to EBITDA ratio of 0.72, indicating prudent financial management.
Return on capital employed (ROCE) averages a healthy 24.88%, signalling efficient use of capital to generate earnings. However, growth metrics over five years show no increase in sales or EBIT, reflecting a stable but non-expansive growth profile. Institutional holdings stand at a moderate 19.67%, suggesting a balanced ownership structure.
Recent Financial Trends Show Peak Quarterly Performance
Short-term financial trends as of March 2026 are positive, with quarterly net sales reaching a high of ₹182.34 crores. Profit before depreciation, interest, and tax (PBDIT) also peaked at ₹62.59 crores, while profit before tax less other income (PBT less OI) stood at ₹56.27 crores. The company reported its highest quarterly profit after tax (PAT) of ₹48.88 crores during this period.
Interest expenses, while at their highest quarterly level of ₹2.44 crores, remain manageable given the strong interest coverage ratio. These financial results underpin the stock’s recent price strength and all-time high achievement.
Market Capitalisation and Grade Overview
Sudeep Pharma is classified as a small-cap company, with a MarketsMOJO Mojo Score of 64.0 and a current Mojo Grade of Hold, upgraded from a previous ungraded status on 22 May 2026. This rating reflects a balanced view of the company’s valuation and performance metrics as of the latest assessment.
The stock’s recent outperformance relative to the Sensex and its sector peers, combined with strong financial and technical indicators, have culminated in this milestone price level.
Summary
Sudeep Pharma Ltd’s stock reaching an all-time high of Rs.856.10 on 16 Jun 2026 marks a significant achievement for the company and its shareholders. Supported by strong quarterly financials, a solid balance sheet, and sustained positive price momentum, the stock has outperformed both its sector and the broader market over multiple time frames. While valuation multiples remain elevated, they reflect the market’s confidence in the company’s current standing. The mildly bullish technical trend and increased delivery volumes further reinforce the stock’s robust position in the Pharmaceuticals & Biotechnology sector.
